# Niagen Bioscience, Inc. (NAGE)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/niagen-bioscience-inc/ JSON: https://steadybase.io/company/niagen-bioscience-inc.json Checked Nov 10, 2026. Latest filing read: Nov 4, 2026.

## Company

- Legal name: Niagen Bioscience, Inc.
- Ticker: NAGE (Nasdaq)
- SEC CIK: 0001386570
- Industry: Medicinal Chemicals & Botanical Products (SIC 2833)
- Headquarters: Los Angeles, CA
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: niagenbioscience.com
- Investor relations: https://investors.niagenbioscience.com/overview/default.aspx
- Next earnings date: Feb 2, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $129.4M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/0001386570-26-000013-index.html
- Operating income: $16.3M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/0001386570-26-000013-index.html
- Net income: $17.4M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/0001386570-26-000013-index.html
- SG&A: $62.6M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/0001386570-26-000013-index.html
- Employees: 117 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/cdxc-20251231.htm
- Shares outstanding: 79,196,903 as of Oct 30, 2026 (10-Q filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000056/0001386570-26-000056-index.html
- Auditor: Crowe LLP, Costa Mesa, California, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/cdxc-20251231.htm

## Business

, a California corporation and wholly-owned subsidiary of Cody (Acquisition Sub), and ChromaDex, Inc. (Merger). Subsequent to the signing of the Merger Agreement, Cody merged with and into a Delaware corporation. On June 20, 2008, Cody amended its articles of incorporation to change its name to ChromaDex Corporation. On April 25, 2016, ChromaDex Corporation became listed on the Nasdaq Capital Market (Nasdaq).

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/cdxc-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $129.4M | $16.3M | $17.4M | $62.6M |
| Dec 31, 2024 | $99.6M | $7.7M | $8.6M | $47.8M |
| Dec 31, 2023 | $83.6M | -$5.6M | -$4.9M | $51.4M |
| Dec 31, 2022 | $72.0M | -$18.6M | -$16.5M | $56.6M |
| Dec 31, 2021 | $67.4M | -$27.1M | -$27.1M | $64.7M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/niagen-bioscience-inc.json

## Officers and directors

- Rob Fried, Chief Executive Officer. Source: 8-K filed Nov 4, 2026, https://www.sec.gov/Archives/edgar/data/1386570/000138657026000057/ex991pressrelease-q32026.htm
- Robert N. Fried, Chief Executive Officer. Source: Form 4 filed Jul 8, 2026, https://www.sec.gov/Archives/edgar/data/1386570/000141795226000002/0001417952-26-000002-index.htm
- Ozan Pamir, Chief Financial Officer. Source: Form 4 filed Jul 8, 2026, https://www.sec.gov/Archives/edgar/data/1386570/000183468126000001/0001834681-26-000001-index.htm
- Carlos Luis Lopez, SVP, General Counsel. Source: Form 4 filed Jul 8, 2026, https://www.sec.gov/Archives/edgar/data/1386570/000204250926000001/0002042509-26-000001-index.htm
- Frank Jaksch Jr., Chairman of the Board and Director. Source: 10-K filed Mar 4, 2026, https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/cdxc-20251231.htm
- Ann Cohen, Director. Source: 10-K filed Mar 4, 2026, https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/cdxc-20251231.htm
- Gary Ng, Director. Source: 10-K filed Mar 4, 2026, https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/cdxc-20251231.htm
- Hamed Shahbazi, Director. Source: 10-K filed Mar 4, 2026, https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/cdxc-20251231.htm
- Kristin Patrick, Director. Source: 10-K filed Mar 4, 2026, https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/cdxc-20251231.htm
- Steven Rubin, Director. Source: 10-K filed Mar 4, 2026, https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/cdxc-20251231.htm
- Wendy Yu, Director. Source: 10-K filed Mar 4, 2026, https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/cdxc-20251231.htm

## Recent 8-K events

- Nov 4, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000057/cdxc-20261104.htm
- Aug 4, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000042/cdxc-20260804.htm
- Jun 29, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000035/cdxc-20260624.htm
- May 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000031/cdxc-20260506.htm
- Mar 19, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000017/cdxc-20260319.htm
- Mar 4, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000014/cdxc-20260304.htm
- Feb 26, 2026: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000003/cdxc-20260224.htm
- Dec 22, 2025: Item 1.01, Entry into a material definitive agreement; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1386570/000138657025000030/cdxc-20251218.htm
- Nov 6, 2025: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1386570/000138657025000025/cdxc-20251106.htm
- Nov 4, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1386570/000138657025000021/cdxc-20251104.htm

## Insider trades (Form 4)

- Nov 14, 2025: Ozan Pamir (Chief Financial Officer) bought 6,685.4 shares, about $45,616. Source: https://www.sec.gov/Archives/edgar/data/1386570/000183468125000005/0001834681-25-000005-index.htm

## What management said

- "During the third quarter, we navigated near-term commercial headwinds while continuing to generate positive adjusted EBITDA and $2.6 million in operating cash flow and make tangible progress across the Niagen platform" Rob Fried, Chief Executive Officer (8-K filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000057/ex991pressrelease-q32026.htm

## Latest filings

- 8-K filed Aug 4, 2026: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000042/cdxc-20260804.htm
- 10-K filed Mar 4, 2026: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/cdxc-20251231.htm
- 10-Q filed Aug 4, 2026: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000043/cdcx-20260630.htm
- DEF 14A filed Apr 29, 2026: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000022/cdxc-20260429.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/